A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Clinical trial NCT07589595 · RECRUITING

Trial details

NCT number: NCT07589595
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cognitive Dysfunction Lewy Body Disease Synucleinopathies Amyloid

Start date: 2026-05-20
Primary completion: 2028-08-01
Enrollment: 350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.